At the end of November 2018 there were 926 companies on AIM, with the total market value of London’s growth market £98.3bn. This compares with 928 companies at the end of October 2018 when AIM’s market value was £102.4bn. Excluding readmissions and reverse takeovers, there were two new arrivals and 4 departures in November.
Onto the newcomers…
Renalytix AI PLC (AIM: RENX) is a developer of artificial intelligence (“AI”) enabled clinical diagnostic solutions for kidney disease.
The Group raised £22.25m through a placing, US subscription and restricted offer to shareholders of EKF Diagnostics Holdings (AIM:EKF) at a price 121p share. The market capitalisation on AIM admission was £65.12m with US based Mount Sinai Health System, a large integrated health care system, holding a…
Register to continue reading this article.
Already a member? Login
For access to the top news and insights from the investment worldREGISTER FREE TODAY